Products containing cannabidiol (CBD) – overview

Implementation guide by the technical platform for delimitation issues of the FOPH, the FSVO and Swissmedic

Products containing cannabidiol (CBD) are gaining popularity in Switzerland. Unlike THC (tetrahydrocannabinol), CBD is not subject to the Narcotics Act because it does not produce a comparable psychoactive effect. However, this does not mean that CBD can simply be added to random preparations at will or advertised arbitrarily.

Products can only be marketed legally if they comply with the legislation of the country where it is placed on the market. Depending on the classification, the corresponding Swiss legislation is applied.

This Information sheet provides an overview of the various CBD-containing raw materials and products offered by suppliers and their classification and marketability according to the current legal situation. It is intended primarily as an implementation guide for identifying the competent authorities and promoting consistent implementation. At the same time, it aims to raise awareness of the legal requirements among possible suppliers.